Sola develops and markets epigenetic tests for the detection of gynaecological cancer. The first product on the market is the WID®-easy test for the detection of uterine body cancer.
https://sola-diagnostics.com/en/patients/
company data |
|
| employees: | <= 5 |
| legal form: | Gesellschaft mit beschränkter Haftung |
| commercial register number: | 533383m |
| founding date: | 2020 |
| Mitglied im Cluster: | |
export countries: |
|
| World-wide | |
products and services: |
|
|
WID®-easy Test https://sola-diagnostics.com/en/patients/ |
|
contact information |
|
| street: | Ing.-Etzl-Straße 9 |
| ZIP code: | 6020 |
| city: | Innsbruck |
| country: | Österreich |
| phone: | +436769037365 |
| email: | info@sola-diagnostics.com |
| website: | https://www.sola-diagnostics.com |
|
contact: |
Dr. Peter Kayatz |
| function: | |
| phone: | +43 676 9037 365 |
| email: | kayatz@sola-diagnostics.com |
-
competences and specialization
- Cancer
- diagnostics
- epigenetics
- gynaecology
- personalised medicine
- preventive medicine